Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects including weight gain and acne. Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators including [tamoxifen]. Anastrozole was first approved for use in the United States in 1995. It is grouped under the following drug class(es): Antineoplastic agents and Fertility agents. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Asiolex, Nastrosa and Arimidex. Its PubChem CID is 2187.
Anastrozole
| CAS No | 120511-73-1 |
|---|---|
| Molecular Formula | C17H19N5 |
| Molecular Weight | 293.4 g/mol |
| Synonyms | 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer.
The listed CAS number is 120511-73-1.
The listed molecular formula is C17H19N5.
The listed molecular weight is 293.4 g/mol.
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile.
The source lists Asiolex, Nastrosa and Arimidex.